Literature DB >> 7918347

Affinity of neuroleptics for D1 receptor of human brain striatum.

S Kanba1, E Suzuki, S Nomura, T Nakaki, G Yagi, M Asai, E Richelson.   

Abstract

We determined the inhibition-dissociation constant (Ki) of a number of neuroleptics for D1 receptors of normal human brain tissue using [3H]SCH23390 [R-(+)-8-chloro-2,3,4,5-tetrahydro-3-methyl-5-phenyl-1H-3[benzazepine-7- ol]. SCH23390 had the highest affinity with a Ki of 0.76 nM. Among clinically used drugs, propericiazine showed the highest affinity with a Ki of 10 nM. When neuroleptics were classified according to chemical structures, the Ki values were as follows. Phenothiazines ranged from 10 nM to 250 nM. Butyrophenones ranged from 45 nM to 250 nM. Thioxanthenes ranged from 12 nM to 340 nM. Orthopramines were more than 10,000 nM. The Ki values for the binding site of this study were significantly correlated with those reported in studies using animal brain. The possible relationship between D1 receptors and negative symptoms is discussed.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7918347      PMCID: PMC1188606     

Source DB:  PubMed          Journal:  J Psychiatry Neurosci        ISSN: 1180-4882            Impact factor:   6.186


  18 in total

1.  Comparative doses and costs of antipsychotic medication.

Authors:  J M Davis
Journal:  Arch Gen Psychiatry       Date:  1976-07

2.  Antipsychotic drug doses and neuroleptic/dopamine receptors.

Authors:  P Seeman; T Lee; M Chau-Wong; K Wong
Journal:  Nature       Date:  1976-06-24       Impact factor: 49.962

3.  [3H]neurotensin(8-13) binds in human brain to the same sites as does [3H]neurotensin but with higher affinity.

Authors:  K S Kanba; S Kanba; A Nelson; H Okazaki; E Richelson
Journal:  J Neurochem       Date:  1988-01       Impact factor: 5.372

Review 4.  Therapeutic potential of selective D-1 dopamine receptor agonists and antagonists in psychiatry and neurology.

Authors:  J L Waddington
Journal:  Gen Pharmacol       Date:  1988

5.  Antagonism by neuroleptics of neurotransmitter receptors of normal human brain in vitro.

Authors:  E Richelson; A Nelson
Journal:  Eur J Pharmacol       Date:  1984-08-17       Impact factor: 4.432

Review 6.  The dopamine D1 receptor: biochemical and behavioral aspects.

Authors:  P H Andersen; E B Nielsen
Journal:  Adv Exp Med Biol       Date:  1986       Impact factor: 2.622

7.  Characterization of the binding of 3H-SCH 23390, a selective D-1 receptor antagonist ligand, in rat striatum.

Authors:  W Billard; V Ruperto; G Crosby; L C Iorio; A Barnett
Journal:  Life Sci       Date:  1984-10-29       Impact factor: 5.037

8.  Negative and deficit symptoms in schizophrenia do respond to neuroleptics.

Authors:  S C Goldberg
Journal:  Schizophr Bull       Date:  1985       Impact factor: 9.306

9.  Histamine H1 receptors in human brain labelled with [3H]doxepin.

Authors:  S Kanba; E Richelson
Journal:  Brain Res       Date:  1984-06-18       Impact factor: 3.252

10.  Dopamine receptor subtype imbalance in schizophrenia.

Authors:  E J Hess; H S Bracha; J E Kleinman; I Creese
Journal:  Life Sci       Date:  1987-04-13       Impact factor: 5.037

View more
  4 in total

1.  A method to estimate in vivo D2 receptor occupancy by antipsychotic drugs.

Authors:  R A Roemer; E Richelson; C Shagass; L Leventhal
Journal:  J Psychiatry Neurosci       Date:  1996-11       Impact factor: 6.186

2.  Effects of typical and atypical antipsychotic drugs on rat brain muscarinic receptors.

Authors:  Katerina Zavitsanou; Vu H Nguyen; Mei Han; Xu Feng Huang
Journal:  Neurochem Res       Date:  2007-03       Impact factor: 3.996

3.  Differential effects of the antipsychotics haloperidol and clozapine on G protein measures in mononuclear leukocytes of patients with schizophrenia.

Authors:  S Avissar; G Roitman; G Schreiber
Journal:  Cell Mol Neurobiol       Date:  2001-12       Impact factor: 5.046

Review 4.  Effects of newer antipsychotics on extrapyramidal function.

Authors:  Daniel Tarsy; Ross J Baldessarini; Frank I Tarazi
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.